Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KMPH

Zevra Therapeutics (KMPH) Stock Price, News & Analysis

Zevra Therapeutics logo

About Zevra Therapeutics Stock (NASDAQ:KMPH)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$4.48
$6.27
52-Week Range
N/A
Volume
64,100 shs
Average Volume
189,500 shs
Market Capitalization
$200.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive KMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KMPH Stock News Headlines

Here's the last trade you should make before heading out for the weekend tomorrow.
Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.
Zevra Therapeutics closes sale of Rare Disease PRV for $150M
Zevra Therapeutics price target raised to $25 from $23 at Canaccord
Zevra Therapeutics price target raised to $22 from $20 at Guggenheim
Zevra Therapeutics reports Q4 EPS (67c), consensus (40c)
See More Headlines

KMPH Stock Analysis - Frequently Asked Questions

Zevra Therapeutics, Inc. (NASDAQ:KMPH) released its quarterly earnings data on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). Zevra Therapeutics had a negative net margin of 328.56% and a negative trailing twelve-month return on equity of 16.12%.

Zevra Therapeutics (KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Meta Platforms (META), SCYNEXIS (SCYX), BioCryst Pharmaceuticals (BCRX), Zoom Communications (ZM) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
3/30/2022
Today
7/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KMPH
Employees
22
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.56 million
Net Margins
-328.56%
Pretax Margin
-335.26%

Debt

Sales & Book Value

Annual Sales
$10.72 million
Price / Cash Flow
23.28
Book Value
$3.63 per share
Price / Book
N/A

Miscellaneous

Free Float
34,125,000
Market Cap
$200.47 million
Optionable
Optionable
Beta
2.16

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:KMPH) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners